Accrued Expenses and Other Current Liabilities |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
| Accrued Expenses and Other Current Liabilities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
| Accrued expenses and other current liabilities | Note 6 - Accrued expenses and other current liabilities:
Accrued expenses and other current liabilities are comprised of the following as of March 31, 2026 and December 31, 2025:
The majority of other accrued expenses and current liabilities relate to research and development (“R&D”) consumables received by the Company but not yet billed by the suppliers. |
|||||||||||||||||||||||||||||||||||||||||||||